BioSpectrum Asia - August 2025

Resurging Funding Catapults APAC BIOTECH STARTUPS

Asia-Pacific's biotech startup scene is on the cusp of a renaissance. After a tough 2024 marked by shrinking venture capital, 2025 is showing revived investor enthusiasm and a rebound in funding-especially for oncology, gene therapy, and Al-driven drug discovery. With 9,905 life sciences startups now active across the region, APAC Countries are leveraging scientific innovation, government support, and new incubators to move beyond service roles and develop world-class therapeutic assets. Let's take a closer look at Asia’s startup ecosystem, evolution of investor sentiment over the past few years, and buoying biotech areas.

ARTICLES

Biotech’s Resurgence: Innovation Amid Market Disruption or A Generational Opportunity in Innovation

Resurging Funding Catapults APAC Biotech Startups

Australia searches for the next CSL

APAC building on enough supply network for radiopharmaceuticals

The Future Formula: What’s Driving Recruitment Innovation in Pharma

INTERVIEWS

"HSA is adopting a forward-looking 5P Strategy to tackle challenges”

Adjunct Professor
(Dr) Raymond Chua,
CEO, Health Sciences Authority (HSA), Singapore

“ASEAN has become an important fulcrum in the global pharmaceutical production supply chain”

Dr Jun Liu,
CEO and Executive Director, BioDlink

“We plan to enter India, Japan, Thailand, and Vietnam to improve the safety of researchers”

Aden (Seong-Ho) Do,
Chief Executive Officer, Connietec, South Korea

“UK-India Free Trade Agreement helps deepen Genomics Collaboration”

Dr Gordon Sanghera,
Co-founder and Chief Executive Officer,
Oxford Nanopore Technologies, the UK